Furthermore, the action of TRPV1 was validated in vitro using the competitive antagonist capsazepine and in vivo using the allosteric inhibitor SB-366791 which not only demonstrated reduced viral infection, but also mitigated pancreatic viral burden, inflammation and damage. Here, TRPV1 is linked to viral infectious disease.